发明名称 Ipilimumab (INN) - krav I basispatent
摘要 The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
申请公布号 NO2012001(I2) 申请公布日期 2016.02.29
申请号 NO20120000001C 申请日期 2012.01.09
申请人 发明人
分类号 A61K38/00;A61K38/17;A61K39/00;A61K39/395;A61K45/00;A61P29/00;A61P31/12;A61P31/14;A61P31/18;A61P35/00;A61P37/00;A61P37/02;A61P37/06;A61P37/08;C07K;C07K14/00;C07K14/705;C07K14/715;C07K14/725;C07K16/00;C07K16/28;C07K16/42;C07K19/00;C12N5/06;C12N5/10;C12N15/02;C12N15/09;C12N15/12;C12N15/13;C12P21/02;C12P21/08;C12R1/91;G01N33/53;G01N33/564;G01N33/566;G01N33/577 主分类号 A61K38/00
代理机构 代理人
主权项
地址